Sun Pharma gets USFDA nod for migraine injection

R. Yegya Narayanan Coimbatore | Updated on June 22, 2011

Sun Pharmaceutical Industries Ltd has announced that the USFDA has granted approval for its subsidiary for its Abbreviated New Drug Application (ANDA) to market a generic version of Sumatriptan Succinate injection, 6 mg (base)/0.5ml.

According to the company, this is the first ANDA approval for a Sumatriptan AutoInjector. Annual sale for Sumatriptan Succinate injections in the US is approximately $190 million.

Sumatriptan Succinate injection is indicated for the acute treatment of migraine attacks with or without aura and acute treatment of cluster headache episodes.

Published on June 22, 2011

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor